Rosalind Advisors Inc. Purchases 47,423 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Rosalind Advisors Inc. boosted its holdings in COMPASS Pathways plc (NASDAQ:CMPS) by 6.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 781,423 shares of the company’s stock after acquiring an additional 47,423 shares during the quarter. COMPASS Pathways accounts for approximately 3.1% of Rosalind Advisors Inc.’s holdings, making the stock its 13th largest position. Rosalind Advisors Inc. owned approximately 1.14% of COMPASS Pathways worth $4,923,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Logos Global Management LP boosted its holdings in COMPASS Pathways by 349.3% in the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock worth $7,001,000 after purchasing an additional 901,050 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of COMPASS Pathways by 86.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,027,868 shares of the company’s stock worth $8,552,000 after buying an additional 477,868 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of COMPASS Pathways by 1,518.4% in the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock worth $1,593,000 after acquiring an additional 247,500 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in COMPASS Pathways by 34.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 148,134 shares of the company’s stock valued at $933,000 after acquiring an additional 38,145 shares during the last quarter. Finally, AdvisorShares Investments LLC lifted its holdings in COMPASS Pathways by 13.5% in the second quarter. AdvisorShares Investments LLC now owns 60,882 shares of the company’s stock valued at $362,000 after acquiring an additional 7,243 shares during the period. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CMPS shares. Maxim Group cut their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Royal Bank of Canada reduced their target price on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research note on Monday, September 9th. Canaccord Genuity Group reduced their price objective on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Finally, HC Wainwright lowered their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $30.67.

COMPASS Pathways Trading Down 3.4 %

Shares of COMPASS Pathways stock opened at $4.52 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The company has a fifty day moving average of $6.54 and a 200 day moving average of $7.02. The company has a market capitalization of $309.12 million, a P/E ratio of -2.05 and a beta of 2.29. COMPASS Pathways plc has a fifty-two week low of $4.05 and a fifty-two week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same period in the previous year, the firm posted ($0.67) EPS. On average, sell-side analysts anticipate that COMPASS Pathways plc will post -2.35 earnings per share for the current fiscal year.

Insider Activity at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of COMPASS Pathways stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the transaction, the insider now directly owns 6,905,774 shares of the company’s stock, valued at $41,779,932.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 4.25% of the stock is owned by insiders.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.